Participating Faculty
David Sclar

Boeing Distinguished Professor
Health Policy & Administration

Director
Pharmacoeconomics & Pharmacoepidemiology
Research Unit

Washington State University
Pullman, WA 99164-6510

Ph.D., 1988, Business Administration & Pharmacy
University of South Carolina

Phone: 509-335-8039
Fax: 509-335-0162
Email: sclar@mail.wsu.edu

 

Research Interests:
Pharmacoeconomics, Pharmacoepidemiology, and Health Policy

Research Summary:
Dr. Sclar's research interests focus on issues involving pharmacoeconomics, pharmacoepidemiology, and health policy, and have been supported by $5.7 million in grants from government agencies, foundations, and the pharmaceutical industry.

Representative Publications:

Robison LM, Sclar DA, Skaer TL. (2005) Datapoints: trends in ADHD and stimulant use among adults: 1995-2002. Psychiatr Serv. 56(12):1497.

Robison LM, Skaer TL, Sclar DA. (2005) Is Attention-Deficit Hyperactivity Disorder (ADHD) Diagnoses in Adults? An Examination of US Office-Based Physician Visits, 1995-2000. Int J Pharm Med;18(6):375-386.

Louie SG, Sclar DA, Gill MA. (2005) Aralast: a new {alpha}(1)-protease inhibitor for treatment of {alpha}-antitrypsin deficiency. Ann Pharmacother. 39(11):1861-9.

Sclar DA, Evans MA, Skaer TL, Robison LM, Chung KC, Poulios NS. 2005 Economic and Epidemiologic Modeling of Full-Length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM), in Previously Treated Patients with Hemophilia A. Comparison with B-Domain Deleted rFVIII (BDDrFVIII), and Utility of Potential Viral Transmission Reduction Due to Plasma/Albumin-Free Status. Drugs in Research and Development 2005;6(3):149-156.

Key BD, Reed R, Sclar DA. (2005) First-order Economizing: Organizational Adaptation and the Elimination of Waste in the U.S. Pharmaceutical Industry. J Managerial Issues, 17(4):511-527.

Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poulios NS. (2003) Anti-D Immunoglobulin in the Treatment of Immune Thrombocytopenic Purpura in Adults in the United Kingdom: An Evaluation of Clinical Outcomes and Resource Utilization. Proceedings of the 43rd Annual Scientific Meeting of the British Society for Haematology. Glasgow, Scotland. British Journal of Haematology 2003;121(Suppl 1):94.

Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poulios NS. (2003) Economic Modeling of Full-length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM), Versus B-Domain Deleted rFVIII (BDDrFVIII) in Previously Treated Persons with Hemophilia A. Proceedings of the 19th Congress of the International Society on Thrombosis and Haemostasis. Birmingham, England. July 17, 2003. Journal of Thrombosis and Haemostasis ;89(Suppl 1):1140

Skaer TL*, Sclar DA, Robison LM. Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States 1990-1998. Does Type of Insurance Influence Access to Innovation? Diabetes Educator 2002;28(3):in press.

Sclar DA, Skaer TL, Robison LM. Methodologic Issues in the Economic Appraisal of Antidepressant Pharmacotherapy. International Clinical Psychopharmacology 2002;17:in press.

Skaer TL, Sclar DA, Robison LM. Economics of Antidepressant Pharmacotherapy. Journal of Clinical Psychiatry 2002;63:in press.

Robison LM, Skaer TL, Sclar DA, Galin RS. Is the Prevalence of Attention-Deficit / Hyperactivity Disorder Increasing Among U.S. Girls? Trends in Diagnosis and the Prescribing of Stimulants. CNS Drugs 2002;16(2):129-137.

Morningstar BA*, Sketris IS, Kephart GA, Comeau DA, Whelan AM, Putnam WB, Burge FR, Flowerdew GD, Sclar DA. Population-Based Trends in Antihypertensive Utilization Among Beneficiaries of the PharmaCare Program of Nova Scotia, Canada. Canadian Journal of Clinical Pharmacology 2002;9(4):176-183.